Value Investing Philosophy And Biomarin Pharmaceutical Inc. (NASDAQ: BMRN)?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that New Data to be Presented for BioMarin’s VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

BMRN belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Biomarin Pharmaceutical Inc. is $16.48B. A total of 0.98 million shares were traded on the day, compared to an average of 1.31M shares.

In the most recent transaction, BIENAIME JEAN JACQUES sold 1,000 shares of BMRN for 86.71 per share on Mar 06 ’24. After the transaction, the Director now owns 560,203 company shares. In a previous transaction on Mar 05 ’24, FUCHS HENRY J sold 35,341 shares at 85.18 per share. BMRN shares that President, Worldwide R&D owns now total 212,117.

Among the insiders who sold shares, Ajer Jeffrey Robert disposed of 4,000 shares on Mar 05 ’24 at a per-share price of $87.07. This resulted in the EVP, Chief Commercial Officer holding 94,047 shares of BMRN after the transaction. In another insider transaction, BIENAIME JEAN JACQUES sold 1,000 shares at $85.51 per share on Mar 05 ’24. Company shares held by the Director now total 561,203.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BMRN has a high of $100.38 and a low of $76.02.

As of this writing, BMRN has an earnings estimate of $0.33 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of $0.49 per share and a lower estimate of $0.21. The company reported an EPS of $0.21 in the last quarter, which was -8.70% lower than expectations of $0.23.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $26.25, while its Total Shareholder’s Equity was $4.27B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.36.

Most Popular

Related Posts